Schizophrenia/Psychosis

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

It is critical to recognize the early signs of schizophrenia and provide timely intervention to prevent full-blown psychosis in adolescents.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

Learn more about how to best assess and treat tardive dyskinesia.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Learn more about the critical link between early adversity and psychosis, and the need for targeted interventions and preventive measures.

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

Early intervention in schizophrenia enhances recovery, reduces symptoms, and improves quality of life through coordinated specialty care programs across the US.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Learn more about the latest advancements in schizophrenia treatment and the ongoing battle against stigma during Mental Health Awareness Month.

Check out the pipeline updates from April!

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.